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Alternative splicing of premessenger RNAs is a key step in
the gene expression process, which allows the synthesis of
diﬀerent products from the same gene and contributes to
increase the complexity of the proteome coded by a limited
number of genes. Specialized high-throughput technologies
(RNA-Seq, splicing-sensitive microarrays) aiming at analyz-
ing alternative splicing in normal or pathological situations
have allowed to make a promising step forward in basic and
translational molecular oncology by identifying a variety of
cancer-associated splicing variants. However, modiﬁcation
of alternative splicing is among the myriad of alterations
present in cancer cells and whether splicing alteration is a
cause or a consequence of cancer remains to be elucidated.
Themainfocusofthisspecialissueistohighlightsomeof
the mechanisms involved in splicing alteration in cancer and
to present new evidence demonstrating the involvement of
alternative splicing alterations in diﬀerent steps and aspects
of cancer initiation and progression.
To highlight the applications of large-scale approaches in
the search for relevant cancer-associated splicing events, S.
Germann and colleagues give an overview of the studies that
have been carried out so far using such strategies. This has
allowed to identify sets of functionally related genes whose
expression is altered at the splicing level in cancer cells and
to characterize some of the factors which control speciﬁc
splicing programs that are deregulated in tumors.
The other reviews give a series of speciﬁc examples
of cancer-associated splicing variants. S. Druillennec and
colleagues address how alternative splicing modiﬁes the
physiological and pathological functions of a variety of
protein kinases. Taking several examples of membrane-
associated or cytosolic kinases, they explain more particu-
larly how the oncogenic properties of this important class of
factors between speciﬁc splicing isoforms.
More speciﬁcally, K. Holzmann and colleagues summa-
rize the various splicing alterations that aﬀect, in diﬀerent
tumor types, the transcripts encoding the ﬁbroblast growth
factor receptors (FGFR) 1–3, at the level of their IgIII loop.
Splicing-induced variations in this domain, which occur
naturally during embryonic development and are regulated
in a tissue-speciﬁc manner, directly aﬀect the interactions
between the receptors and their ligands and have profound
consequences on their activity. In cancer cells, alterations in
FGFR2 splicing are involved in the epithelial-mesenchymal
transition, an important step in the formation of metastases.
In their paper, Hilmi and colleagues focus on the
alternative splicing of vascular endothelial growth factor
(VEGF), which produces isoforms with opposite functions
in the control of angiogenesis, a process involved in the
progression and metastasis of several cancers. They discuss
the emerging possibility of targeting angiogenesis more
accurately by modulating the splicing of VEGF transcripts
through the factors that control it.
J. Wei and colleagues review our current knowledge of
the functional diversity of protein isoforms that compose the
p53 family, encoded by the TP53, TP63, and TP73 genes.
Evidence shows that the aberrant expression of some of these
isoforms in cancer cells contributes to tumor progression
and may explain in some cases the resistance of tumors to
therapeutic treatments.2 Journal of Nucleic Acids
Altogether those review articles illustrate how cancer
cells may divert the natural properties of tissue-speciﬁc or
developmentally regulated splicing variants to alter cellular
functions and lead to a malignant phenotype or to a
propagation of the tumor. This also underlines the need for
a better understanding of the molecular mechanisms that
control such splicing alterations.
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